Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Advancis Likely To Change Name Following Ruling In Favor Of Sanofi-Aventis

This article was originally published in The Pink Sheet Daily

Executive Summary

Court rules that Advancis name infringes on Sanofi-Aventis' trademark and orders the two firms to submit a proposed order by Oct. 23.

You may also be interested in...



MiddleBrook Aims To Address $600 Million Strep Market With Moxatag

Company plans to launch the first once-daily amoxicillin formulation for patients over 12 in the fall.

MiddleBrook Aims To Address $600 Million Strep Market With Moxatag

Company plans to launch the first once-daily amoxicillin formulation for patients over 12 in the fall.

Advancis Gets “Refuse To File” Letter For Pulsatile Amoxicillin NDA

Firm may need to manufacture commercial-sized quantities of antibiotic in order for FDA to accept the submission.

Related Content

Topics

UsernamePublicRestriction

Register

ID1132090

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel